Results 241 to 250 of about 30,994 (308)

Pathogenesis of nonfamilial somatotroph adenomas.

J Clin Endocrinol Metab
Ben-Shlomo A, Melmed S.
europepmc   +1 more source

Calcium-Sensing Receptor Regulation of Gastrointestinal Hormone Secretion.

Endocr Rev
Anjom-Shoae J, Veedfald S, Conigrave AD, Horowitz M, Feinle-Bisset C.   +4 more
europepmc   +1 more source

Error in the Visual Abstract.

JAMA Intern Med
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Actions of GIP

Peptides, 1981
Two structurally similar peptides were isolated from a preparation of GIP using an HPLC system. The major peptide corresponds to GIP1-42 and the minor has the sequence GIP3-42. GIP1-42 has both insulinotropic and somatostatinotropic activities, whereas GIP3-42 has only insignificant activity.
Raymond A Pederson, Christopher H S Mcintosh, J C Brown   +2 more
exaly   +3 more sources

Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease

Peptides, 2020
Accumulating evidence suggests that glucose-dependent insulinotropic polypeptide (GIP) in addition to its involvement in type 2 diabetic pathophysiology may be involved in the development of obesity and the pathogenesis of cardiovascular disease. In this
Filip K Knop, Natasha Chidekel Bergmann, Lærke Smidt Gasbjerg   +2 more
exaly   +2 more sources

The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update

Diabetes, obesity and metabolism, 2021
The incretin hormones glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) have their main physiological role in augmenting insulin secretion after their nutrient‐induced secretion from the gut.
M. Nauck, D. Quast, J. Wefers, A. Pfeiffer   +3 more
semanticscholar   +1 more source

Dual GIP/GLP-1 receptor agonists: new advances for treating type-2 diabetes.

Annales d'Endocrinologie, 2023
Glucagon-like peptide-1 (GLP-1) receptor agonists currently occupy a privileged place in the management of type-2 diabetes (T2D). Dual glucose-dependent insulinotropic polypeptides (GIP/GLP-1) have been recently developed.
A. Scheen
semanticscholar   +1 more source

GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment.

Pharmacological Research, 2022
The intestinal hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-2 (GLP-2) are key regulators of postprandial bone turnover in humans.
M. Gabe, Kirsa Skov-Jeppesen, L. Gasbjerg, S. Schiellerup, Christoffer Martinussen, S. Gadgaard, G. A. Boer, Jannika Oeke, L. Torz, S. Veedfald, M. Svane, K. N. Bojsen-Møller, S. Madsbad, J. Holst, B. Hartmann, M. Rosenkilde   +15 more
semanticscholar   +1 more source

GIP or not GIP? That is the question

Trends in Pharmacological Sciences, 2003
Glucose-dependent insulinotropic polypeptide (GIP) is a gastrointestinal hormone that is released during a meal and facilitates the disposal of both glucose and fat. Because of the insulinotropic action of GIP, this hormone has been considered as a potential therapy of type 2 diabetes, where insulin secretion is inadequate.
openaire   +2 more sources

GIP’s effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3–30)NH2

Bone, 2020
Infusion of the incretin hormone glucose-dependent insulinotropic polypeptide (GIP) suppresses the bone resorption marker carboxy-terminal type 1 collagen crosslinks (CTX). Using separate and combined infusions of the selective GIP receptor (GIPR) antagonist, GIP(3-30)NH2, and GIP, we investigated how GIPR inhibition affects bone turnover markers.
Lærke S. Gasbjerg, Bolette Hartmann, Mikkel B. Christensen, Amalie R. Lanng, Tina Vilsbøll, Niklas R. Jørgensen, Jens J. Holst, Mette M. Rosenkilde, Filip K. Knop   +8 more
openaire   +4 more sources